Physical health in schizophrenia: A challenge for antipsychotic therapy

European Psychiatry

Volumn 25, Issue SUPPL. 2, 2010, Pages S6-

  Heald, A ^a  

^a LEIGHTON HOSPITAL   (United Kingdom)

Author keywords

Antipsychotic therapy; Cardiovascular risk; Diabetes; Health assessment; Physical health; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ABDOMINAL OBESITY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DISEASE ASSOCIATION; HEALTH HAZARD; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; MENTAL HEALTH; METABOLIC SYNDROME X; OBESITY; PATIENT MONITORING; PHYSICAL DISEASE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SCHIZOPHRENIA; SELF ESTEEM; SIDE EFFECT; WEIGHT GAIN;

EID: 77954162423     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(10)71700-4     Document Type: Article

References (43)

1. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
2. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062.
3. Allison D.B., Fontaine K.R., Moonseong H., Mentore J.L., Cappelleri J.C., Chandler L.P., et al. The distribution of Body Mass Index among Individuals with and without Schizophrenia. J Clin Psychiatry 1999, 60:215.
4. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity.
5. Banerji M.A., Lebowitz J., Chaiken R.L., Gordon D., Kral J.G., Lebowitz B.D. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 2007, 273:E425.
6. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997, 171:502-508.
7. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004, 65(Suppl. 7):4-18.
8. De Hert M., Dekker J.M., Wood D., Kahl K.G., Moller H.J. Cardiovascular Disease and Diabetes in People with Severe Mental Illness. Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009, 24:412-424.
9. De Hert M., Schreurs V., Sweers K., Van Eyck D., Hanssens L., Sinko S., et al. Typical and atypical antipsychotics differentially affect longterm incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 2008, 101:295-303.
10. De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2006, 2:14.
11. Dolder C.R., Lacro J.P., Jeste D.V. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 2003, 65:156-162.
12. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497. Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
13. Faulkner G., Cohn T., Remington G., Irving H. Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophr Res 2007, 90:174-178.
14. Field A.E., Coakley E.H., Must A., Spadano J.L., Laird N., Dietz W.H., et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001, 161:1581-1586.
15. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005, 80:45-53.
16. Goldman L.S. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999, 60(Suppl. 21):10-15.
17. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
18. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
19. Herrán A., de Santiago A., Sandoya M., Fernández M.J., Diez-Manrique J.F., Vázquez-Barquero J.L. Determinants of smoking behaviour in outpatients with schizophrenia. Schizophr Res 2000, 41:373-381.
20. Holt R.I., Bushe C., Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link?. J Psychopharmacol 2005, 19(6 Suppl.):56-65.
21. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332:73-78.
22. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
23. Kahn R. Metabolic syndrome-what is the clinical usefulness?. Lancet 2008, 371:1892-1893.
24. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
25. Kato M.M., Currier M.B., Gomez C.M., Hall L., Gonzalez-Blanco M. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 2004, 6:74-77.
26. Lawrence D.M., Holman C.D., Jablensky A.V., Hobbs M.S. Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. Br J Psychiatry 2003, 182:31-36.
27. Maguire G.A. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002, 63(Suppl. 4):56-62.
28. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
29. Montejo A.L. The need for routine physical healthcare in schizophrenia. Eur Psychiatry 2010, 25:S3-S5.
30. Mozaffarian D., Kamineni A., Prineas R.J., Siscovick D.S. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med 2008, 168:969-978.
31. Mulnier H.E., Seaman H.E., Raleigh V.S., Soedamah-Muthu S.S., Colhoun H.M. Mortality in people with Type 2 diabetes in the UK. Diabet Med 2006, 23:516-521.
32. Nasrallah H.A., Meyer J.M., Goff D.C., McEvoy J.P., Davis S.M., Stroup T.S., et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006, 86:15-22.
33. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl. 1):1-93.
34. Osborn D.P., Levy G., Nazareth I., Petersen I., Islam A., King M.B. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry 2007, 64:242-249.
35. Osby U., Correia N., Brandt L., Ekbom A., Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000, 45:21-28.
36. Sattar N., McConnachie A., Shaper A.G., Blauw G.J., Buckley B.M., de Craen A.J., et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008, 371:1927-1935.
37. Smith N.L., Barzilay J.I., Kronmal R., Lumley T., Enquobahrie D., Psaty B.M. New-onset diabetes and risk of all-cause and cardiovascular mortality. Diabet Med 2006, 29:2012-2017.
38. Subramaniam M., Chong S.A., Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003, 48:345-347.
39. Turrone P., Kapur S., Seeman M.V., Flint A.J. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002, 159:133-135.
40. Ucok A., Incesu C., Aker T., Erkoc S. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry 2007, 22:328-333.
41. Ward A., Ishak K., Proskorovsky I., Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 2006, 28:1912-1921.
42. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
43. Yusuf S., Hawken S., Ounpuu S., Bautista L., Franzosi M.G., Commerford P., et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005, 366:1640-1649.